Rheumatoid arthritis (RA) is an autoimmune disease causing inflammation and destruction of joints and tissues, influenced by genetic and environmental factors. Key diagnostic biomarkers include rheumatoid factor and anti-citrullinated protein antibodies, with imaging revealing joint damage. Treatment options comprise disease-modifying antirheumatic drugs (DMARDs) and biological agents like infliximab and adalimumab.